Microsoft word - cv emmanuel stip.doc

Emmanuel Stip, M.D.
Membre actif, département de psychiatrie CHUM
Professeur titulaire, Université de Montréal
 Formation et diplômes

CES, Médecine et biologie du sport, Université d’Angers DEUG, Philosophie, Université d’Angers, Paris VIII CES, Psychiatrie, Université d’Angers Maîtrise, Sciences neurologiques, Université de Montréal C.S.P.Q, Psychiatrie, Corporation professionnelle des médecins du Québec  Au CHUM depuis :

 Intérêts cliniques
Neurosciences de la schizophrénie Neuromodulation  Intérêts académiques

Recherche (titulaire de la Chaire de schizophrénie de l’Université de Montréal)
Enseignement et supervision

 Prix et distinctions
Prix annuel de l’AMPQ (1989) Michael Smith Award (2005) Prix J.M. Cleghorn d’excellence et de leadership en recherche clinique (2012)  Intérêts administratifs

Directeur du département de psychiatrie de l’Université de Montréal depuis
 Publications / Présentations / Livres récents
Luck D & Stip E. Neuro-imagerie et santé mentale. Cahiers scientifiques de Sablier J, Stip E, Jacquet P, Giroux S, Pigot H, Franck N; Mobus Group. Ecological assessments of activities of daily living and personal experiences with Mobus, an assistive technology for cognition: a pilot study in schizophrenia. Assist Technol. 2012 Summer;24(2):67-77. Zhornitsky S, Aubin G, Desfossés J, Rizkallah E, Pampoulova T, Lipp O, Chiasson JP, Stip E, Potvin S. Predictors of Community Functioning in Schizophrenia and Substance Use Disorder Patients. Community Ment Health J. 2012 Jul 31. [Epub ahead of print] Guillaume F, Guillem F, Tiberghien G, Stip E. Mismatched expressions decrease face recognition and corresponding ERP old/new effects in schizophrenia. Neuropsychology. 2012 Sep;26(5):568-77. Epub 2012 Jun 11. Lungu O, Stip E. Agenesis of corpus callosum and emotional information processing in schizophrenia. Front Psychiatry. 2012;3:1. Epub 2012 Feb 3. Stip E, Lungu OV, Anselmo K, Letourneau G, Mendrek A, Stip B, Lipp O, Lalonde P, Bentaleb LA. Neural changes associated with appetite information processing in schizophrenic patients after 16 weeks of olanzapine treatment. Translational Psychiatry. 2012 : 2 (e128, doi:10.1038/tp.2012.53). Lungu O, Anselmo K, Letourneau G, Mendrek A, Stip B, Lipp O, Lalonde P, Ait Bentaleb L, Stip E. Neuronal correlates of appetite regulation in patients with schizophrenia: Is there a basis for future appetite dysfunction? Eur Psychiatry. 2012 Apr 27. [Epub ahead of print] Lungu O, Barakat M, Laventure S, Debas K, Proulx S, Luck D, Stip E. The Incidence and Nature of Cerebellar Findings in Schizophrenia: A Quantitative Review of fMRI Literature. Schizophr Bull. 2012 Jan 20. [Epub ahead of print] Moteshafi H, Stip E. Comparing tolerability profile of quetiapine, risperidone in schizophrenia and affective disorders: a meta-analysis. Expert Opinion on Drug Homayoun S, Nadeau-Marcotte F, Luck D, Stip E. Subjective and Objective Cognitive Dysfunction in Schizophrenia - is there a Link? Front Psychol. 2011;2:148. Briand C, Reinharz D, Lesage A, Nicole L, Stip E, Lalonde P, Villeneuve K, Planet-Sultan S. [Implementation in Quebec of the Integrated Psychological Treatment (IPT) for people with schizophrenia: five years later]. Sante Ment Que. 2010 Stip E, Abdel-Baki A, Bloom D, Grignon S, Roy MA. [Long-acting injectable antipsychotics: an expert opinion from the Association des médecins psychiatres du Québec]. Can J Psychiatry. 2011 Jun;56(6):367-76. French. Honer WG, Macewan GW, Gendron A, Stip E, Labelle A, Williams R, Eriksson H; for the STACK Study Group. A randomized, double-blind, placebo-controlled study of the safety and tolerability of high-dose quetiapine in patients with persistent symptoms of schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2011. Mendrek A, Stip E. Sexual dimorphism in schizophrenia: is there a need for gender-based protocols? Expert Rev Neurother. 2011 Jul;11(7):951-9. Zhornitsky S, Stip E, Desfossés J, Pampoulova T, Rizkal ah E, Rompré PP, Bentaleb LA, Lipp O, Chiasson JP, Gendron A, Potvin S. Evolution of Substance use, Neurological and Psychiatric Symptoms in Schizophrenia and Substance use Disorder Patients: A 12-Week, Pilot, Case-Control Trial with Quetiapine. Front Psychiatry. 2011;2:22. Igue R, Potvin S, Bah R, Stip E, Bouchard RH, Lipp O, Gendron A, Kouassi E. Soluble interleukin-2 receptor levels correlated with positive symptoms during quetiapine treatment in schizophrenia-spectrum disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Aug 15;35(7):1695-8. Dumais A, Potvin S, Joyal C, Al aire JF, Stip E, Lesage A, Gobbi G, Côté G. Schizophrenia and serious violence: a clinical-profile analysis incorporating impulsivity and substance-use disorders. Schizophr Res. 2011;130(1-3):234-7. Zhornitsky S, Potvin S, Moteshafi H, Dubreucq S, Rompré PP, Stip E. Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders: a systematic review of the placebo-controlled monotherapy and add-on trials. Int Clin Psychopharmacol. 2011;26(4):183-92. Zhornitsky S, Potvin S, Aubin G, Stip E. Relationship between insight into cognition, extrapyramidal symptoms and mental illness in schizophrenia. Aust N Z J

Source: http://chumpsychiatrie.ca/wp-content/uploads/2012/09/CV-Emmanuel-Stip.pdf